A carregar...
THE FIRST CLINICAL EXPERIENCE WITH AFATINIB IN RUSSIAN FEDERATION
Randomized clinical trials results have shown the advantage of non-selective EGFR tyrosine kinase inhibitor 2nd generation – afatinib compared with platinum-based chemotherapy in adenocarcinoma EGFR-positive patients in both the first and second-line of treatment. Shown significant improvement in PF...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado em: |
Remedium Group LLC
2016-12-01
|
| Colecção: | Медицинский совет |
| Assuntos: | |
| Acesso em linha: | https://www.med-sovet.pro/jour/article/view/1407 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|